Back to News
Market Impact: 0.38

UBS reiterates Franco Nevada stock Buy rating on Panama restart potential

FNV
Analyst InsightsCorporate EarningsCompany FundamentalsCorporate Guidance & OutlookCapital Returns (Dividends / Buybacks)Commodities & Raw Materials
UBS reiterates Franco Nevada stock Buy rating on Panama restart potential

UBS reiterated a Buy on Franco-Nevada and set a $310 price target versus the current $236.93 share price, citing upside from a possible Cobre Panama restart and earnings growth that the market has not priced in. Franco-Nevada also reported strong Q4 2025 results, with EPS of $1.85 versus $1.65 expected and revenue of $597.3 million versus $536.09 million expected, while annual revenue rose to $1.9 billion and net income to $1.1 billion. The stock remains supported by a 91% gross margin and 18 consecutive years of dividend increases, though the Cobre Panama restart timeline remains uncertain.

Analysis

FNV is less a pure gold beta here and more a reopening optionality trade on one asset that has outsized contribution to cash flow. The market is likely underappreciating how quickly margin leverage can reassert itself if even a partial restart occurs, because the business has already absorbed the fixed-hit of the disruption and incremental ounces should drop through at very high rates. That makes the next 2-4 quarters more about sentiment re-rating and estimate revisions than about spot bullion direction. The competitive setup also matters: royalty/streaming names should outperform high-cost producers if the restart stays delayed, because they retain exposure to upside without the capex and operational risk of a mine restart. But if the restart is approved, FNV becomes the cleanest way to express a recovery in Panama without taking balance-sheet or jurisdictional operating risk, which should compress the discount versus miners that need to spend heavily to grow. The second-order effect is that capital may rotate out of lower-quality precious metals equities into FNV and similar toll-collectors on any proof of life from Panama. The main risk is not commodity prices but timing slippage: each month of ambiguity can grind the multiple because the market will keep treating the restart as a binary headline, not an earnings bridge. The contrarian view is that expectations may already be too bullish on the speed of monetization; if revised fiscal terms dilute economics even modestly, the near-term upside to estimates could disappoint despite a successful restart process. Over 6-12 months, the trade is favorable, but the entry point matters because the stock is now pricing a meaningful probability of good news already.